CDK4/6抑制剂治疗三阴性乳腺癌的研究进展  

Advances in the treatment of triple-negative breast cancer with CDK4/6 inhibitors

作　　者：朱秀之 陈力 纪磊 高雨 王中华 ZHU Xiuzhi;CHEN Li;JI Lei;GAO Yu;WANG Zhonghua(Department of Breast Surgery,Key Laboratory of Breast Cancer in Shanghai,Fudan University Shanghai Cancer Center,Department of Oncology,Shanghai Medical College,Fudan University,Shanghai 200032,China)

机构地区：[1]复旦大学附属肿瘤医院乳腺外科上海市乳腺肿瘤重点实验室复旦大学上海医学院肿瘤学系

出　　处：《中国癌症杂志》2019年第11期899-905,共7页China Oncology

基　　金：北京乳腺病防治学会乳腺癌预防与诊治科研基金（2016）;上海市抗癌协会青年医生“雏鹰”项目（2018)(SACA-CY1B02）

摘　　要：细胞周期的调控机制在肿瘤的发生、发展中发挥着重要作用。多项研究表明,在雌激素受体阳性、人类表皮生长因子受体阴性的乳腺癌患者中,细胞周期蛋白依赖性激酶4/6(cyclin-dependent kinase 4/6,CDK4/6)抑制剂具有较好的疗效,然而其在三阴性乳腺癌患者中的疗效仍需进一步探讨。Cyclin D-CDK4/6-INK4-Rb-E2F信号通路因具有调控细胞周期检查点的作用,被认为是乳腺癌潜在的治疗靶点。寻找三阴性乳腺癌与CDK4/6抑制剂关联的生物标志物,探究合理的药物配伍,筛选能从中获益的靶向人群,对临床工作具有重要意义。对CDK4/6抑制剂在三阴性乳腺癌的研究进展进行综述,探讨其应用前景及优化手段。The regulatory mechanism of cell cycle plays an important role in the occurrence and development of tumors.In recent years,a number of studies have shown that cyclin-dependent kinase 4/6(CDK4/6)inhibitors have good efficacy in patients with estrogen receptor-positive,human epidermal growth factor receptor-negative breast cancer,but their efficacy in patients with triple-negative breast cancer is still controversial.Cyclin D-CDK4/6-INK4-Rb-E2 F signaling pathway is considered as a potential therapeutic target for breast cancer due to its role in regulating cell cycle check points.It is of great significance to explore the molecular markers related to CDK4/6 inhibitors for triple-negative breast cancer,guide rational drug combination,and screen the population of triple-negative breast cancer patient who can benefit from this drug.In this article,we reviewed the research progress of CDK4/6 inhibitors in triple-negative breast cancer,and discussed their application prospects and optimization methods.

关 键 词：细胞周期蛋白依赖激酶4/6 细胞周期蛋白D和E 三阴性乳腺癌 视网膜母细胞瘤蛋白质 雄激素受体 

分 类 号：R737.9[医药卫生—肿瘤]